Latest features in GaBI Journal, 2017, Issue 3
Patent expiry and costs for anticancer medicines for clinical use
A survey of Australian prescribers’ views on the naming and substitution of biologicals
Biosimilars in Italy: what do real-world data reveal?
Physician associations comment on FDA’s interchangeability guidance
Pharmacovigilance, traceability and building trust in biosimilar medicines
Value-added medicines: how repurposed medicines bring value to patients and pharmacists
Healthcare professionals will accept generic HIV treatments
Source URL: https://gabi-journal.net/20173-gabi-journal-table-of-contents.html
Copyright ©2024 GaBI Journal unless otherwise noted.